Global Cell Therapy Market, Price, Product and Clinical Pipeline Outlook 2024 Report

“Global Cell Therapy Market, Price, Product and Clinical Pipeline Outlook 2024” Report Highlights:

* Market Analysis by Application in Various Therapeutic Areas
* Comprehensive Insight On Clinical Pipeline: 664 Cell Therapies
* Cell Therapy Market Opportunity More Than US$ 25 Billion by 2024
* Marketed Cell Therapies: 21
* Price and Product Insight By Region/Country
* Cell Therapy Clinical Pipeline Overview
* Collaborations and Acquisition in the Cell Therapy Segment
* Regional Analysis of the Cell Therapy Market

Download Report Sample Weblink:

https://www.kuickresearch.com/report-global-cell-therapy-market,-price,-product-and-clinical-pipeline-outlook-2024.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Prologue to Cell Therapy
1.1 An Overview to Cells and Their Therapeutic Ability
1.2 Unique Features of Cellular Therapeutics
1.2.1 Stem Cells - Key Agents of Cellular Based Therapeutics
1.2.2 Key Advantages of Cell Therapy over Other Existing Therapeutics

2. Mechanism of Cell Therapy Treatment
2.1 Principle of Cell Therapy
2.1.1 Cell Therapy and the Immune Response
2.1.2 Mechanism of Regenerative Cell Therapy
2.2 Role of Surface Markers and Their Targeting
2.2.1 Targeting the Signal Cascades
2.2.2 Targeting the Microenvironment
2.3 Allogeneic Stem Cell Therapy
2.4 Autologous Stem Cell Therapy

3. Stem Cells - Their Application and Contribution in the Establishment of Cell Therapy Market
3.1 Origin of Stem Cells
3.1.1 Embryonic Stem Cells
3.1.2 Adult Stem Cells
3.1.3 Induced Pluripotent Stem Cells (iPSCs)
3.2 Exploring Stem Cell’s Ability to Differentiate
3.2.1 Totipotent Stem Cells
3.2.2 Pluripotent Stem Cells
3.2.3 Multipotent Stem Cells
3.2.4 Unipotent Stem Cells

4. Cell Therapy Market Analysis by Application in Various Therapeutic Areas
4.1 Cell Therapy for Cardiovascular Disease
4.1.1 Myocardial Infarction
4.1.2 Heart Failure
4.2 Cell Therapy for Neurological Disorders
4.2.1 Parkinson’s Diseases
4.2.2 Alzheimer’s Diseases
4.2.3 Huntington’s Diseases
4.3 Cell Therapy for Inflammatory Diseases
4.3.1 Asthma
4.3.2 Arthritis
4.3 Cell Therapy for Diabetes
4.3.3 Type 1 diabetes
4.3.4 Type 2 diabetes
4.4 Cell Therapy for Cancer
4.4.1 Stem Cells and Their Therapeutic Role in Cancer
4.4.2 Role of Surface Markers and Their Targeting
4.4.3 Targeting the Signal Cascades
4.4.4 Targeting the Microenvironment

5. Product and Price Analysis of Cell Therapy Approved in US
5.1 Apligraf and Dermagraft
5.2 Carticel
5.3 ChondroCelect
5.4 Epicel
5.5 Holoclar
5.6 Kymriah
5.7 Provenge
5.8 Yescarta

6. Product and Price Analysis of Cell Therapy Products Approved in Europe
6.1 Spherox
6.2 Strimvelis

7. Product and Price Analysis of Cell Therapy Approved in South Korea
7.1 Cartistem
7.2 Cupistem
7.3 Hearticellgram

8. Product and Price Analysis of Cell Therapy Approved in Japan
8.1 HeartSheet
8.2 Temcell

9. Current Status of the Global Cell Therapy Market
9.1 Overview of the Global Cell Therapy Market
9.2 Industrial Insight into the Cell Therapy Market - Key Players and Their Contribution
9.3 Cell Therapy Clinical Pipeline Overview
9.4 Investments in the Cell Therapy Market

10. Global Cell Therapy Market Trends
10.1 Cell Therapy Enhancing the Effect of Existing Therapeutic Methods
10.2 Cell Therapy Market More Oriented Towards Immune Cells
10.3 Involvement of Both Academia and Industries to Enhance Progress of Cell Therapy Studies
10.4 Impact of Cell Therapy on the Drug Delivery Market
10.4.1 Direct Delivery Methods
10.4.2 Indirect Delivery Method

11. Collaborations and Acquisition in the Cell Therapy Segment
11.1 Collaborations
11.2 Acquisition

12. Regional Analysis of the Cell Therapy Market
12.1 North America
12.2 Europe
12.3 Asia
12.3.1 China
12.3.2 Japan
12.3.3 South Korea
12.3.4 India
12.4 Rest of the World
12.4.1 Africa
12.4.2 Middle East
12.4.3 South America

13. Global Cell Therapy Market Dynamics
13.1 Growth Promoting Parameters of the Cell Therapy Market
13.2 Commercial Challenges of the Cell Therapy Market

14. Future Prospectus and Scope of the Cell Therapy Market

15. Global Cell Therapy Clinical Pipeline by Company, Indication and Phase
15.1 Unknown
15.2 Research
15.3 Preclinical
15.4 Clinical
15.5 Phase-0
15.6 Phase-I
15.7 Phase-I/II
15.8 Phase-II
15.9 Phase-II/III
15.10 Phase-III
15.11 Preregistration
15.12 Registered

16. Marketed Cell Therapy Clinical Insight
16.1 Immuncell-LC
16.2 Adipocell (Anterogen)
16.3 Provenge
16.4 CureXcell
16.5 Holoclar
16.6 MACI
16.7 Carticel
16.8 MyoCell
16.9 Laviv
16.10 Prochymal
16.11 Grafix
16.12 Gintuit
16.13 Autologous Mesenchymal Stem Cell Therapy - Pharmicell
16.14 Cartistem
16.15 CHONDRON
16.16 BioCart
16.17 NuCel
16.18 Dendritic Cell-Activated Cytokine-Induced Killer Cells
16.19 Chondrotransplant DISC
16.20 Urocell
16.21 CellSpray

17. Competitive Landscape
17.1 AlloCure
17.2 Arteriocyte Medical Systems
17.3 Athersys Inc.
17.4 Baxter Healthcare Corporation
17.5 Bone Therapeutics
17.6 Celgene Corporation
17.7 Cell Medica
17.8 Cellerant Therapeutics
17.9 FibrocellScinence
17.10 Forticell Bioscience
17.11 Genzyme Corporation
17.12 Green Cross Cell
17.13 Histogenics Corporation
17.14 InnovacellBiotechnologie AG
17.15 Intrexon Corporation
17.16 Intercytex
17.17 ISTO Technologies
17.18 Macrocure
17.19 Mesoblast
17.20 Molmed
17.21 Nuo Therapeutics Inc
17.22 OmniCyte
17.23 Opexa Therapeutics
17.24 Organogenesis
17.25 Pharmicell
17.26 TCA Cellular Therapy
17.27 Stem Cell Inc.
17.28 Teva Pharmaceuticals
17.29 Tigenix
17.30 Vericel Corporation

Figure 1-1: Basic Overview of Cell Therapy
Figure 1-2: Historical Insight into Cell Therapy
Figure 1-3: Key Goals of using Cell Therapy
Figure 2-1: Mechanism of Paracrine Signaling
Figure 2-2: Demonstration of the Endocrine Signaling
Figure 2-3: Illustration of the Autocrine Signaling
Figure 2-4: Paracrine Signaling in Heart Repair
Figure 2-5: Common Sources of Cells in Cell Therapy
Figure 2-6: Requirements of an Ideal Cell Donor in Cell Therapy
Figure 2-7: Steps in Allogeneic Stem Cell Therapy
Figure 2-8: Steps in Autologous Stem Cell Therapy
Figure 3-1: Application of Cell Therapy in Various Clinical Indications
Figure 3-2: Global - Cell Therapy Type by Donor Cell Source (%).2018
Figure 3-3: Global - Stem Cell v/s Non Stem Cell Therapy Studies (%), 2018
Figure 3-4: Type of Stem Cells on the Basis of Origin
Figure 3-5: Global - Cell Therapy Product Source (%), 2018
Figure 3-6: Type of Stem Cells and Their Ability to Differentiate
Figure 3-7: Global - Type of Immune Cells Used in Cell Therapy (%), 2018
Figure 4-1: Global - Mortality Caused by Non Communicable Disease (%), 2018
Figure 4-2: Cell Therapy - Clinical Trials by Indication (%), 2018
Figure 4-3: Cell Therapy for Cardiovascular Disease
Figure 4-4: Overview of Stem Cell Therapy in Cardiovascular Disease
Figure 4-5: Cell Therapy in Neurological Disorders
Figure 4-6: Cell Therapy in Treatment of Alzheimer's disease
Figure 4-7: Cell Therapy in Diabetes
Figure 5-1: Apligraf - Cost per Use (US$/Patient), 2018
Figure 5-2: Carticel - Price Analysis (US$/Patient), 2018
Figure 5-3: ChondroCelect - Price Analysis (US$/Patient), 2018
Figure 5-4: Epicel - Price Analysis per 1% Total Body Surface Area (US$/Patient), 2018
Figure 5-5: Kymriah - Therapy Price Analysis (US$/Year), 2018
Figure 5-6: Provenge - Price Analysis (US$/Year), 2018
Figure 5-7: Yescarta - Price Analysis (US$), 2018
Figure 6-1: Spherox - Price Analysis (US$/Patient), 2018
Figure 6-2: Strimvelis - Price Analysis (US$ and Euro), 2018
Figure 7-1: Cartistem - Price Analysis (US$/Dose), 2018
Figure 7-2: Hearticellgram - Price Analysis (US$/Patient), 2018
Figure 8-1: HeartSheet - Treatment Cost Analysis (US$/ Administration), 2018
Figure 8-2: Temcell - Price Analysis (US$/72 Million Cells), 2018
Figure 9-1: Global - Cell Therapy Clinical Pipeline by Phase (%), 2018 till 2024
Figure 9-2: Global - Cell Therapy Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 9-3: Global - Cell Therapy Clinical Pipeline by Discontinued Trials(%),2018 till 2024
Figure 9-4: Global - Cell Therapy Clinical Pipeline by Discontinued Trials (Number), 2018 till 2024
Figure 10-1: Global - Preference of Cell Type in Cell Therapy (%), 2018
Figure 10-2: Cell Therapy - Funding in Industry and Academia (%), 2018
Figure 12-1: Cell Therapy - Trials Conducted by Region (%), 2018
Figure 12-2: Europe - Cell Therapy Clinical Trial Analysis by Region (%), 2018
Figure 12-3: Asia - Cell Therapy Clinical Trial by Region (%), 2018
Figure 12-4: Cell Therapy-Comparative Cost Analysis by Region (US$), 2018
Figure 12-5: Rest of the World - Cell Therapy Clinical Trial by Region (%), 2018
Figure 13-1: Global - Key Factors Driving the Cell Therapy Market
Figure 13-2: Global - Cell Therapy Market Challenges
Figure 14-1: Future Objectives of the Cell Therapy market
Figure 14-2: Global - Cell Therapy Market Opportunity (US$ Billion), 2018 -2024
Figure 14-3: Key Developments Impacting the Future Cell Therapy Market
Figure 17-1: Arteriocyte Medical Systems Clinical Pipeline
Figure 17-2: Bone Therapeutics Clinical Pipeline
Figure 17-3: Celgene Clinical Pipeline
Figure 17-4: Cellerant Therapeutics Clinical Pipeline
Figure 17-5: Fibrocell Science Clinical Pipeline
Figure 17-6: Genzyme Clinical Pipeline
Figure 17-7: Intrexon Clinical Pipeline
Figure 17-8: ISTO Clinical Pipeline
Figure 17-9: Mesoblast Clinical Pipeline
Figure 17-10: Molmed Clinical Pipeline
Figure 17-11: Pharmicell Clinical Pipeline
Figure 17-12: Tigenix Clinical Pipeline
Figure 17-13: Vericel Corporation Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.